期刊
JOURNAL OF INVESTIGATIVE DERMATOLOGY
卷 136, 期 7, 页码 1330-1336出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jid.2016.03.006
关键词
-
类别
资金
- National Cancer Institute of the National Institutes of Health [K08CA155035]
- Melanoma Research Alliance Young Investigator Award
- Max Kade Foundation
- Rene Touraine Foundation
Up to 18% of melanomas harbor mutations in the neuroblastoma rat-sarcoma homolog (NRAS). Yet, decades of research aimed to interfere with oncogenic RAS signaling have been largely disappointing and have not resulted in meaningful clinical outputs. Recent advances in disease modeling, structural biology, and an improved understanding of RAS cycling as well as RAS signaling networks have renewed hope for developing strategies to selectively block hyperactive RAS function. This review discusses direct and indirect blocking of activated RAS with a focus on current and potential future therapeutic approaches for NRAS mutant melanoma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据